Entity Details

Primary name RYR1
Entity type gene
Source Source Link

Details

PrimaryID6261
RefseqGeneNG_008866
SymbolRYR1
Nameryanodine receptor 1
Chromosome19
Location19q13.2
TaxID9606
Statuslive
SourceGenomegenomic
SourceOriginnatural
CreationDate1998-08-25
ModificationDate2021-06-13

Ontological Relatives

UniProt IDsRYR1_HUMAN

GO terms

Show/Hide Table
GOName
GO:0001666 response to hypoxia
GO:0003151 outflow tract morphogenesis
GO:0005219 ryanodine-sensitive calcium-release channel activity
GO:0005245 voltage-gated calcium channel activity
GO:0005262 calcium channel activity
GO:0005509 calcium ion binding
GO:0005516 calmodulin binding
GO:0005524 ATP binding
GO:0005737 cytoplasm
GO:0005790 smooth endoplasmic reticulum
GO:0005886 plasma membrane
GO:0005887 integral component of plasma membrane
GO:0005938 cell cortex
GO:0006816 calcium ion transport
GO:0006936 muscle contraction
GO:0014701 junctional sarcoplasmic reticulum membrane
GO:0014802 terminal cisterna
GO:0014808 release of sequestered calcium ion into cytosol by sarcoplasmic reticulum
GO:0015278 calcium-release channel activity
GO:0016529 sarcoplasmic reticulum
GO:0030018 Z disc
GO:0030659 cytoplasmic vesicle membrane
GO:0031000 response to caffeine
GO:0031301 integral component of organelle membrane
GO:0031674 I band
GO:0033017 sarcoplasmic reticulum membrane
GO:0034220 ion transmembrane transport
GO:0034704 calcium channel complex
GO:0042383 sarcolemma
GO:0043588 skin development
GO:0043931 ossification involved in bone maturation
GO:0048741 skeletal muscle fiber development
GO:0048763 calcium-induced calcium release activity
GO:0051209 release of sequestered calcium ion into cytosol
GO:0051289 protein homotetramerization
GO:0051480 regulation of cytosolic calcium ion concentration
GO:0070062 extracellular exosome
GO:0071277 cellular response to calcium ion
GO:0071313 cellular response to caffeine
GO:1903779 regulation of cardiac conduction
GO:1990425 ryanodine receptor complex

Diseases

Show/Hide Table
Disease IDSourceNameDescription
117000 OMIMCentral core disease of muscle (CCD)Autosomal dominant congenital myopathy, but a severe autosomal recessive form also exists. Both clinical and histological variability is observed. Affected individuals typically display hypotonia and proximal muscle weakness in infancy, leading to the delay of motor milestones. The clinical course of the disorder is usually slow or nonprogressive in adulthood, and the severity of the symptoms may vary from normal to significant muscle weakness. Microscopic examination of CCD-affected skeletal muscle reveals a predominance of type I fibers containing amorphous-looking areas (cores) that do not stain with oxidative and phosphorylase histochemical techniques. The disease is caused by variants affecting the gene represented in this entry.
255320 OMIMMultiminicore disease with external ophthalmoplegia (MMDO)Clinically heterogeneous neuromuscular disorder. General features include neonatal hypotonia, delayed motor development, and generalized muscle weakness and amyotrophy, which may progress slowly or remain stable. Muscle biopsy shows multiple, poorly circumscribed, short areas of sarcomere disorganization and mitochondria depletion (areas termed minicores) in most muscle fibers. Typically, no dystrophic signs, such as muscle fiber necrosis or regeneration or significant endomysial fibrosis, are present in multiminicore disease. The disease is caused by variants affecting the gene represented in this entry.
145600 OMIMMalignant hyperthermia 1 (MHS1)Autosomal dominant pharmacogenetic disorder of skeletal muscle and is one of the main causes of death due to anesthesia. In susceptible people, an MH episode can be triggered by all commonly used inhalational anesthetics such as halothane and by depolarizing muscle relaxants such as succinylcholine. The clinical features of the myopathy are hyperthermia, accelerated muscle metabolism, contractures, metabolic acidosis, tachycardia and death, if not treated with the postsynaptic muscle relaxant, dantrolene. Susceptibility to MH can be determined with the 'in vitro' contracture test (IVCT): observing the magnitude of contractures induced in strips of muscle tissue by caffeine alone and halothane alone. Patients with normal response are MH normal (MHN), those with abnormal response to caffeine alone or halothane alone are MH equivocal (MHE(C) and MHE(H) respectively). Disease susceptibility is associated with variants affecting the gene represented in this entry.